WallStreetZenWallStreetZen

NASDAQ: SMMT
Summit Therapeutics Inc Stock Ownership - Who owns Summit Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Summit Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Robert W. DugganCo-Chief Executive Officer2026-06-123,810,000$13.12
$49.99MBuy
Mahkam ZanganehCo-Chief Executive Officer2026-06-123,810,000$13.12
$49.99MBuy
Manmeet Singh SoniCOO and CFO2026-06-0425,000$14.46
$361.50kBuy
Robert W. DugganCo-Chief Executive Officer2026-06-04100,000$14.60
$1.46MBuy
Manmeet Singh SoniCOO and CFO2026-06-0425,000$14.43
$360.75kBuy
Mahkam ZanganehCo-Chief Executive Officer2026-06-04100,000$14.60
$1.46MBuy
Manmeet Singh SoniCOO and CFO2025-10-2153,361$18.74
$999.99kBuy
Bhaskar AnandChief Accounting Officer2025-10-2126,680$18.74
$499.98kBuy
Robert W. DugganCo-Chief Executive Officer2025-10-2113,980,789$18.74
$262.00MBuy
Yu XiaDirector2025-10-21533,617$18.74
$10.00MBuy

1 of 2

SMMT insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when SMMT insiders and whales buy or sell their stock.

SMMT Shareholders

What type of owners hold Summit Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Mahkam Zanganeh80.79%644,473,702$10.80BInsider
Robert W. Duggan76.47%610,015,809$10.22BInsider
Yu Xia4.02%32,057,147$537.12MInsider
Maky Zanganeh1.87%14,915,775$249.91MInsider
Manmeet Singh Soni0.39%3,123,603$52.34MInsider
Ankur Dhingra0.05%394,485$6.61MInsider
Bhaskar Anand0.02%159,751$2.68MInsider
Jeff Huber0.01%56,052$939.15kInsider
Baker Bros Advisors LP0.00%32,786$549.33kInstitution
Bakbro0.00%32,786$549.33kInstitution

1 of 3

SMMT vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
SMMT0.01%99.99%Net Buying
BBIO0.10%56.78%Net SellingNet Selling
CORT0.04%99.96%Net BuyingNet Selling
HALO0.11%30.22%Net SellingNet Selling
EXEL0.10%5.67%Net SellingNet Selling
View Top Biotech Stocks

Summit Therapeutics Stock Ownership FAQ

Who owns Summit Therapeutics?

Summit Therapeutics (NASDAQ: SMMT) is owned by 0.02% institutional shareholders, 163.61% Summit Therapeutics insiders, and 0.00% retail investors. Mahkam Zanganeh is the largest individual Summit Therapeutics shareholder, owning 644.47M shares representing 80.79% of the company. Mahkam Zanganeh's Summit Therapeutics shares are currently valued at $10.80B.

If you're new to stock investing, here's how to buy Summit Therapeutics stock.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.